Summary & Overview

HCPCS Level II C9070: Injection, tafasitamab-cxix, 2 mg

HCPCS Level II code C9070 identifies the injectable oncology biologic tafasitamab-cxix in 2 mg units, a targeted monoclonal antibody used in cancer therapy. Nationally, accurate coding for high-cost specialty drugs like tafasitamab-cxix is critical for claims processing, utilization oversight, and patient access to treatment. This publication outlines how payers handle billing for this drug across major national insurers and Medicare.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and billing considerations, payer-specific benchmark contexts, and clinical service context relevant to outpatient infusion settings. The report highlights common modifiers and administrative details used in claims, typical sites of service, and what information is available versus missing from the input.

This summary serves clinicians, billing professionals, and policy analysts seeking a national perspective on coding and administrative handling of C9070 for tafasitamab-cxix, including expected documentation points and where to look for payer-specific guidance.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareC9070HCPCS Level IItafasitamab-cxixoncology druginfusion servicesdrug administrationspecialty pharmacyoutpatient infusionhospital outpatient department

Billing Code Overview

HCPCS Level II code C9070 describes Injection, tafasitamab-cxix, 2 mg. This code represents administration of the monoclonal antibody tafasitamab-cxix in a 2 mg dosage unit. The service type is drug administration for an oncology biologic agent. The typical site of service is outpatient infusion centers or hospital outpatient departments where parenteral oncology treatments are delivered.

Clinical & Coding Specifications

Clinical Context

A 68-year-old patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presents to an outpatient oncology infusion clinic for administration of tafasitamab-cxix. The patient has previously received combination chemotherapy and now is prescribed intravenous monoclonal antibody therapy. Prior to infusion, the patient is screened by the infusion nurse for vital signs, current labs (CBC, CMP), and premedication needs (acetaminophen, antihistamine, corticosteroid per protocol).

The oncology advanced practice provider reviews the order and documents indication, consent, and any prior infusion reactions. Pharmacy prepares the appropriate tafasitamab-cxix dose and labels syringes/vials; billing uses HCPCS Level II code C9070 to report the drug in 2 mg units. The infusion is administered in an outpatient infusion chair or ambulatory infusion suite with continuous monitoring for infusion-related reactions. Post-infusion observation and documentation of tolerance and any adverse events occur before discharge. Subsequent cycles follow the same workflow with documentation of response and toxicity in the electronic medical record.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work required for drug administration or documentation is substantially greater than typical due to complexity (e.g., extensive dose calculations, prolonged infusion management).
`23`	Unusual anesthesia	Rarely used for oncology infusions; applicable if significant anesthesia is required for the infusion procedure.
`52`	Reduced services	Use when planned tafasitamab-cxix administration is partially reduced or incomplete (e.g., abbreviated dose given).
`53`	Discontinued procedure	Use when infusion is started but discontinued due to adverse reaction and cannot be completed.
`55`	Postoperative management only	Not commonly applicable; use if only post-infusion global care is billed separately under specific circumstances.
`56`	Preoperative management only	Not typically applicable; use if only pre-infusion evaluation is billed separately.
`62`	Two surgeons	Use when two qualified clinicians from different specialties are required for a complex procedure related to administration.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare beneficiaries	Use when a PA/NP/CNS performs or assists with the infusion under Medicare rules.
`CQ`	Services provided by a PA in critical access hospital	Use when a physician assistant provides the infusion service in a qualifying facility under payer rules.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	Rare for infusion; use only if anesthesia is medically directed for infusion and meets criteria.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Medical oncology and hematology specialists who prescribe and oversee tafasitamab-cxix therapy.
`363LF0000X`	Infusion Therapy	Registered nurses and infusion specialists who administer monoclonal antibody infusions.
`103T00000X`	Nurse Practitioner	Oncology NPs who manage orders, consent, and follow-up of infusion therapy.
`207LP2900X`	Medical Oncology	Physicians specializing in hematologic malignancies who determine therapy and monitor response.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C83.3`	Diffuse large B-cell lymphoma, unspecified	Most common lymphoma indication for tafasitamab-cxix therapy in relapsed or refractory disease.
`C85.8`	Other specified types of non-Hodgkin lymphoma	Used when a specified subtype of aggressive B-cell lymphoma is the indication for monoclonal antibody therapy.
`C83.9`	Non-follicular lymphoma, unspecified	Used when histology indicates a non-follicular B-cell lymphoma appropriate for targeted monoclonal antibody therapy.
`D47.Z2`	Monoclonal gammopathy, unspecified	May be relevant for related hematologic abnormality surveillance; less common primary indication.
`Z51.11`	Encounter for antineoplastic chemotherapy	Used to indicate the encounter is for administration of antineoplastic therapy including monoclonal antibodies.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Used for billing the professional infusion administration time for the initial hour of tafasitamab-cxix infusion when applicable.
`96366`	Intravenous infusion; each additional hour	Billed for each additional hour of continuous infusion time beyond the first hour when the monoclonal antibody infusion requires extended administration.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Applicable if premedication (e.g., corticosteroid, antihistamine) is given subcutaneously or intramuscularly prior to infusion.
`36415`	Collection of venous blood by venipuncture	Used for required laboratory monitoring (CBC, CMP) drawn before or during therapy cycles.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity	May be used for pre-infusion or follow-up evaluation by the oncology clinician when an E/M visit is separately billable.